Rituximab

Generic Name
Rituximab
Brand Names
MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
Drug Type
Biotech
Chemical Formula
-
CAS Number
174722-31-7
Unique Ingredient Identifier
4F4X42SYQ6
Background

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication

Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions
Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
Associated Therapies
-

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma

The inMIND trial showed Monjuvi + Rituxan + Revlimid improved progression-free survival (PFS) to 22.4 months vs. 13.9 months for placebo in R/R follicular lymphoma. Key secondary endpoints also favored the experimental arm. Monjuvi aims to become a new standard-of-care option, with potential competition from other therapies.
biospace.com
·

Oncology Biosimilars Market Size to Reach USD 35.79 Billion By 2034

The oncology biosimilars market was valued at USD 6.50 billion in 2024 and is projected to reach USD 35.79 billion by 2034, with a CAGR of 18.6%. Factors driving growth include the rising prevalence of cancer, regulatory support, and the development of cost-effective biosimilars. Key trends include the loss of exclusivity of key oncology drugs and support from regulatory bodies. Biosimilars are increasingly used in oncology globally, with segments such as breast cancer and lung cancer dominating the market.
gene.com
·

Press Releases | Monday, Dec 9, 2024

New data at ASH 2024 show Genentech's Columvi and Lunsumio achieve durable remissions, reduce travel burden, and offer subcutaneous options, enhancing lymphoma treatment flexibility and patient experience.
globenewswire.com
·

New and updated data for Roche's fixed-duration Columvi

Roche presented new data on Columvi and Lunsumio at ASH 2024, showing durable remissions and reduced travel burden. Subcutaneous Lunsumio demonstrated non-inferiority to IV treatment, offering a shorter administration time. These results support Roche's efforts to innovate lymphoma treatments.
globenewswire.com
·

Five-year results confirm Roche's Polivy combination

Five-year follow-up of POLARIX study shows positive trend in overall survival for Polivy + R-CHP in first-line DLBCL, fewer subsequent treatments needed, and maintained benefits in progression-free and disease-free survival.
© Copyright 2024. All Rights Reserved by MedPath